These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 23352301)

  • 1. [Update on FGFR3 mutation and multiple regional epigenetic silencing (MRES) phenotype in urothelial carcinogenesis].
    Masson-Lecomte A; Vordos D; de la Taille A; Neuzillet Y; Radvanyi F; Allory Y
    Prog Urol; 2013 Feb; 23(2):96-8. PubMed ID: 23352301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression.
    Vallot C; Stransky N; Bernard-Pierrot I; Hérault A; Zucman-Rossi J; Chapeaublanc E; Vordos D; Laplanche A; Benhamou S; Lebret T; Southgate J; Allory Y; Radvanyi F
    J Natl Cancer Inst; 2011 Jan; 103(1):47-60. PubMed ID: 21173382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast growth factor receptor-3 in urothelial tumorigenesis.
    Iyer G; Milowsky MI
    Urol Oncol; 2013 Apr; 31(3):303-11. PubMed ID: 22285006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.
    Zieger K; Dyrskjøt L; Wiuf C; Jensen JL; Andersen CL; Jensen KM; Ørntoft TF
    Clin Cancer Res; 2005 Nov; 11(21):7709-19. PubMed ID: 16278391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer.
    Otto W; Denzinger S; Bertz S; Gaumann A; Wild PJ; Hartmann A; Stoehr R
    Int J Cancer; 2009 Nov; 125(9):2205-8. PubMed ID: 19621447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Molecular changes in development and progression of urothelial carcinoma].
    Hartmann A
    Verh Dtsch Ges Pathol; 2003; 87():172-84. PubMed ID: 16888910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular characteristics of urothelial neoplasms in children and young adults: a subset of tumors from young patients harbors chromosomal abnormalities but not FGFR3 or TP53 gene mutations.
    Williamson SR; Wang M; Montironi R; Eble JN; Lopez-Beltran A; Zhang S; Fan R; Wang L; Osunkoya AO; Koch MO; Cheng L
    Mod Pathol; 2014 Nov; 27(11):1540-8. PubMed ID: 24743222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.
    Rebouissou S; Hérault A; Letouzé E; Neuzillet Y; Laplanche A; Ofualuka K; Maillé P; Leroy K; Riou A; Lepage ML; Vordos D; de la Taille A; Denoux Y; Sibony M; Guyon F; Lebret T; Benhamou S; Allory Y; Radvanyi F
    J Pathol; 2012 Jul; 227(3):315-24. PubMed ID: 22422578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours.
    van Oers JM; Wild PJ; Burger M; Denzinger S; Stoehr R; Rosskopf E; Hofstaedter F; Steyerberg EW; Klinkhammer-Schalke M; Zwarthoff EC; van der Kwast TH; Hartmann A
    Eur Urol; 2007 Sep; 52(3):760-8. PubMed ID: 17240035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting favourable prognosis of urothelial carcinoma: gene expression and genome profiling.
    van der Kwast TH; Bapat B
    Curr Opin Urol; 2009 Sep; 19(5):516-21. PubMed ID: 19553819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.
    Eltze E; Wild PJ; Wülfing C; Zwarthoff EC; Burger M; Stoehr R; Korsching E; Hartmann A
    Eur Urol; 2009 Nov; 56(5):837-45. PubMed ID: 18945538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.
    López-Knowles E; Hernández S; Malats N; Kogevinas M; Lloreta J; Carrato A; Tardón A; Serra C; Real FX
    Cancer Res; 2006 Aug; 66(15):7401-4. PubMed ID: 16885334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Editorial comment on: FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours.
    Montironi R
    Eur Urol; 2007 Sep; 52(3):768. PubMed ID: 17240042
    [No Abstract]   [Full Text] [Related]  

  • 14. New insights into the influence of cigarette smoking on urothelial carcinogenesis: smoking-induced gene expression in tumor-free urothelium might discriminate muscle-invasive from nonmuscle-invasive urothelial bladder cancer.
    Gabriel U; Li L; Bolenz C; Steidler A; Kränzlin B; Saile M; Gretz N; Trojan L; Michel MS
    Mol Carcinog; 2012 Nov; 51(11):907-15. PubMed ID: 21976419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast growth factor receptor 3 activation plays a causative role in urothelial cancer pathogenesis in cooperation with Pten loss in mice.
    Foth M; Ahmad I; van Rhijn BW; van der Kwast T; Bergman AM; King L; Ridgway R; Leung HY; Fraser S; Sansom OJ; Iwata T
    J Pathol; 2014 Jun; 233(2):148-58. PubMed ID: 24519156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular basis of urinary bladder cancer.
    Al Hussain TO; Akhtar M
    Adv Anat Pathol; 2013 Jan; 20(1):53-60. PubMed ID: 23232572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
    Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
    Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recent advances in bladder urothelial carcinogenesis].
    Pignot G; le Goux C; Bieche I
    Bull Cancer; 2015 Dec; 102(12):1020-35. PubMed ID: 26617115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternative splicing of fibroblast growth factor receptor 3 produces a secreted isoform that inhibits fibroblast growth factor-induced proliferation and is repressed in urothelial carcinoma cell lines.
    Tomlinson DC; L'Hôte CG; Kennedy W; Pitt E; Knowles MA
    Cancer Res; 2005 Nov; 65(22):10441-9. PubMed ID: 16288035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of two major pathways in bladder cancer development.
    Zieger K; Marcussen N; Borre M; Ørntoft TF; Dyrskjøt L
    Int J Cancer; 2009 Nov; 125(9):2095-103. PubMed ID: 19637316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.